Genmab — August 2014
-
nemlig.
-
Genmab står til at få 0,5-1,0 mia. $ alene i royalty om året (med 100% margin) fra Daratumumab
-
http://blogbuster.org han mener at vide at institutionelle investorer sidder på 18%
-
det er ikke så højt
-
og Fidelty som vel stadig er over 5% også?
-
Meddelse ovre på Euroinvestor: The company and capital he runs requires to make decisions on many aspects. One of which can be the need for liquidity.
-
spoke with Mr Stienstra yesterday. All shares are absorbed in the market over the past few months with no significant effect on the share price as a result of his sale.
Sale has no relation with the confidence in Genmab.
Det bliver spændende at få kastet lys over de pivotal Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind